Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Aurora Cannabis Inc (ACB) vs Moderna, Inc. (MRNA) Price & Performance

Aurora Cannabis IncTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

Aurora Cannabis Inc vs Moderna, Inc. — how do they compare? Aurora Cannabis Inc trades at $3.72 (market cap $223.59M), while Moderna, Inc. trades at $63.36 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 108.1× Aurora Cannabis Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Aurora Cannabis Inc nearer its low. Which is the better fit depends on your goals.

ACBMRNA
Market Cap
$223.59M$24.18B
Sector
HealthHealth
52-Week High
$6.23$81.80
52-Week Low
$2.58$22.36
Enterprise Value
$168.09M$20.33B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Aurora Cannabis Inc

Aurora Cannabis (ACB) trades at $3.63, up 25.61% amid a hostile takeover bid from Curaleaf at a 45% premium. The stock shows mixed signals with a neutral technical outlook, while fundamentals reveal revenue growth to $343.29M in 2025 but a net income margin of -38.25% and negative ROE. Cash flow improved to a net positive $1.83M in 2025, though 2026 projections indicate renewed losses.

The takeover offer presents a near-term catalyst, but standalone risks persist including profitability challenges and competitive pressures. Analysts are cautious with a majority hold rating. Investors face a binary outcome: accept the premium bid or navigate ACB's volatile fundamentals.

Moderna, Inc.

Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.

The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Aurora Cannabis Inc

Aurora Cannabis, based in Edmonton, Canada, grows and distributes both medical and recreational cannabis under several brands, including Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. While its main market is Canada, the company has also expanded globally through medical cannabis export agreements.

Read more on ACB

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA